Market
In which non-medical field will Neuralink's N1 implant achieve a milestone by end of 2025?
2
Resolution / Starting Odds
Gaming • 25%
Virtual Reality • 25%
Augmented Reality • 25%
Other • 25%
Neuralink announcements and tech news outlets
Story
Neuralink's N1 Implant with 1,024 Electrodes Promises Thought-Controlled Interaction at 9.5 BPS for Paralysis Patients
Dec 16, 2024, 09:02 AM
Neuralink's N1 implant is being hailed as a groundbreaking technology that could revolutionize the way individuals with paralysis interact with the world. The coin-sized device integrates 1,024 electrodes across 64 ultra-thin threads, achieving a bandwidth of 9.5 Bits Per Second (BPS), which is approximately 50% of normal human capability. This technology allows users to control computers, play games, and type using only their thoughts. Elon Musk has highlighted the potential of Neuralink to restore full body mobility by transferring signals from the motor cortex past spinal injuries, a feat already demonstrated in animals. The advancements in this field are generating significant interest among investors and researchers, as they explore the implications for technology and medicine, particularly in enhancing human capabilities and treating conditions like paralysis.
View original story
Similar markets
Medical rehabilitation • 25%
Gaming • 25%
Communication • 25%
Other • 25%
Significant AI integration • 25%
Other • 25%
Achieves full sensory feedback • 25%
Enables multi-device control • 25%
Other significant milestone • 25%
New treatment for epilepsy • 25%
Enhanced mobility for ALS patients • 25%
Improved communication for paralyzed patients • 25%
Epilepsy • 25%
Other condition • 25%
Depression • 25%
Parkinson's disease • 25%
Other major update • 25%
New software features • 25%
Increased electrode count • 25%
Extended battery life • 25%
Yes • 50%
No • 50%
European Union • 25%
United States • 25%
Asia • 25%
Other • 25%
Other breakthrough • 25%
Blindness treatment • 25%
ALS treatment • 25%
Paralysis treatment • 25%
Battery Design • 25%
Drug Discovery • 25%
Other • 25%
Fusion Energy • 25%
Case study on other neurological conditions • 25%
Case study on paralysis treatment • 25%
Case study on ALS treatment • 25%
No high-profile case study • 25%
Technology • 25%
Healthcare • 25%
Automotive • 25%
Finance • 25%